Adaptive and Collaborators to Present More than 30 Abstracts at 2023 ASH Annual Meeting

Read More

Drug Discovery

Pipeline

Drug Discovery aims to develop pipeline of transformative medicines

TCR Therapeutics

Indication

Discovery

Preclinical

IND-Ready

Clinical

Partner

TCR Therapeutics

Indication

Oncology1

Discovery

Preclinical

IND-Ready

Clinical

First shared cell therapy
Second shared cell therapy
Personalized cell therapy

Partner

Genentech A Member of the Roche Group

Indication

Autoimmune Diseases

Discovery

Preclinical

IND-Ready

Clinical

TCR-Treg

Antibody Therapeutics

Antibody Therapeutics

Indication

Infectious Diseases

Discover

Preclinical

IND-Ready

Clinical

SARS-CoV-2
Influenza A
RSV

1 Product candidates in development as part of our worldwide collaboration and license agreement with Genentech. The first shared and second shared cell therapy product candidates refer to the two lead clinical product candidates selected from our library of TCRs that target cancer antigens present in many cancer patients. Genentech will determine the timing of discussions with, and submissions to, the FDA.